AKAM
43
3
NTAP
64
2
ZBH
60
-2
VRTX
46
2
IP
70
2
CAG
30
4
ACN
47
-2
BAC
50
-3
L
62
2
AFL
46
-3
DE
46
3
T
50
3
VRSN
53
3
V
60
-6
AVGO
20
-5
ETR
68
3
EFX
32
2
URI
53
-2
MCO
73
3
OXY
40
3
AKAM
43
3
NTAP
64
2
ZBH
60
-2
VRTX
46
2
IP
70
2
CAG
30
4
ACN
47
-2
BAC
50
-3
L
62
2
AFL
46
-3
DE
46
3
T
50
3
VRSN
53
3
V
60
-6
AVGO
20
-5
ETR
68
3
EFX
32
2
URI
53
-2
MCO
73
3
OXY
40
3
Financhill
Back

Madrigal Pharmaceuticals 10K Form

Buy
57

MDGL
Madrigal Pharmaceuticals

Last Price:
320.90
Seasonality Move:
35.27%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive MDGL News And Ratings

See the #1 stock for the next 7 days that we like better than MDGL

MDGL Financial Statistics

Sales & Book Value

Annual Sales: $150K
Cash Flow: $-67.76M
Price / Cash Flow: 0
Annual Sales: $35.64
Price / Book: 8.52

Profitability

EPS (TTM): -25.12000
Net Income (TTM): $-518.67M
Gross Margin: $0
Return on Equity: -89.04%
Return on Assets: -62.74%

Madrigal Pharmaceuticals Earnings Forecast

Key Madrigal Pharmaceuticals Financial Ratios

  • The Selling, General & Administrative Expenses for MDGL have been equal to 7,786.67% of Gross Profit Margin.
  • The Interest Expense is -3.40% of Operating Income.
  • Per Share Earnings over the last 23 years have been positive in 8 years.

Madrigal Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: MDGL
CUSIP: 558868
Website: madrigalpharma.com

Debt

Debt-to-Equity Ratio: 0.15
Current Ratio: 5.98
Quick Ratio: 5.79

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

MDGL Technical Analysis vs Fundamental Analysis

Buy
57
Madrigal Pharmaceuticals (MDGL) is a Buy

Is Madrigal Pharmaceuticals a Buy or a Sell?